Neurofibromatoses
10
0
1
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
10%
1 trials in Phase 3/4
29%
2 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (10)
Resiliency Training in Adolescents With NF1 and NF2
Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
Mindful Parenting - A Single Case Experimental Design Study
Phase I Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1)
Dexmedetomidine and Propofol for Pediatric MRI Sedation
Resiliency Training for Adolescent Neurofibromatosis Patients Via Videoconferencing With Skype
The Neurofibromatosis-associated Tumor Biobank
Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas
Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)